

CANCER PREVENTION RESEARCH

TABLE OF CONTENTS

**SPECIAL COLLECTION:
HONORING PAUL F. ENGSTROM, MD,
CHAMPION OF CANCER PREVENTION**

- 215** **Honoring Paul F. Engstrom, MD: A Pioneer of Cancer Prevention**
Margie L. Clapper and Carolyn Y. Fang
- 219** **Navigating the Intersection between Genomic Research and Clinical Practice**
Mary B. Daly
- 223** **A Multi-level Model to Understand Cervical Cancer Disparities in Appalachia**
Electra D. Paskett, Michael L. Pennell, Mack T. Ruffin, Christopher M. Weghorst, Bo Lu, Erinn M. Hade, Juan Peng, Brittany M. Bernardo, and Mary Ellen Wewers
- 229** **Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention**
Margie L. Clapper, Wen-Chi L. Chang, and Harry S. Cooper
- 241** **Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers**
Camille V. Trinidad, Ashley L. Tetlow, Leonidas E. Bantis, and Andrew K. Godwin
- 253** **Addressing Disparities in Cancer Screening among U.S. Immigrants: Progress and Opportunities**
Carolyn Y. Fang and Camille C. Ragin
- 261** **The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions**
Scott D. Siegel, Caryn Lerman, Alex Flitter, and Robert A. Schnoll

RESEARCH ARTICLES

- 273** **Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers**
Altaf Mohammed, Mark Steven Miller, Ronald A. Lubet, Chen S. Suen, Shizuko Sei, Robert H. Shoemaker, Margaret M. Juliana, Fariba L. Moeinpour, and Clinton J. Grubbs
- 283** **Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers**
Ronald A. Lubet, Brandy M. Heckman-Stoddard, Jennifer T. Fox, Fariba Moeinpour, M. Margaret Juliana, Robert H. Shoemaker, and Clinton J. Grubbs
- 291** **A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors**
Leah H. Biller, Chinedu Ukaegbu, Tara G. Dhingra, Carol A. Burke, Yana Chertock, Anuradha Chittenden, James M. Church, Erika S. Koeppe, Brandie H. Leach, Elana Levinson, Ramona M. Lim, Megan Lutz, Erin Salo-Mullen, Rania Sheikh, Gregory Idos, Fay Kastrinos, Elena Stoffel, Jennifer M. Weiss, Michael J. Hall, Matthew F. Kalady, Zsofia K. Stadler, Sapna Syngal, and Matthew B. Yurgelun
- 299** **The Quality of Pap Smears from the Brazilian Cervical Cancer Screening Program According to the Human Development Index**
Ricardo Filipe Alves Costa, Adhemar Longatto-Filho, Fabiana de Lima Vazquez, Céline Pinheiro, Luiz Carlos Zeferino, and José Humberto Tavares Guerreiro Fregnani
- 309** **Economic Evaluation of Tailored Web versus Tailored Telephone-Based Interventions to Increase Colorectal Cancer Screening among Women**
David R. Lairson, Tong Han Chung, Danmeng Huang, Timothy E. Stump, Patrick O. Monahan, Shannon M. Christy, Susan M. Rawl, and Victoria L. Champion

TABLE OF CONTENTS

317 Community-Based Upper Gastrointestinal Cancer Screening in a Randomized Controlled Trial: Baseline Results in a Non-high-incidence Area


Hai-Fan Xiao, Shi-Peng Yan, Yan-fang Chen, Zhaohui Shi, Yan-Hua Zou, Song-lin Zhu, Ke-Kui Xu, Ting Song, and Xian-Zhen Liao

329 Assessing Nurses' Adherence to the See-and-Treat Guidelines of Botswana's National Cervical Cancer Prevention Programme

Lauren G. Johnson, Doreen Ramogola-Masire, Anne M. Teitelman, John B. Jemmott, and Alison M. Buttenheim

ABOUT THE COVER

Inflammation and epidermal growth factor receptor (EGFR) signaling dysregulation play an important role in urinary bladder cancer development. Non-steroidal anti-inflammatory drugs (NSAIDs) and EGFR inhibitors may block bladder tumorigenesis. However, daily dosing of either NSAIDs or EGFR inhibitors can cause gastrointestinal ulceration and acneiform rash, respectively, limiting their continuous use in a clinical prevention setting. To explore the utility of alternative dosing and scheduling of combination regimens, Mohammed and colleagues (in a study beginning on page 273) evaluated chemopreventive efficacy of pulsatile dosing of EGFR inhibitor erlotinib (once/week) combined with intermittent (3 weeks on/off) or continuous low doses of the NSAID naproxen in the OH-BBN induced rat bladder cancer model. All combination regimens tested, including late intervention with intermittent low-dose naproxen and weekly erlotinib combination, exerted robust antitumor effects. These findings demonstrate that significant chemopreventive efficacy could be achieved with alternative intervention regimens designed to reduce the toxicity of agents, and that starting the combination treatments at the time microscopic tumors were present still conferred the efficacy. The photograph on the cover shows a typical histological image of transitional cell carcinoma in the urinary bladder of an untreated female Fischer-344 rat exposed to the carcinogen OH-BBN.



Cancer Prevention Research

13 (3)

Cancer Prev Res 2020;13:215-336.

Updated version Access the most recent version of this article at:
<http://cancerpreventionresearch.aacrjournals.org/content/13/3>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerpreventionresearch.aacrjournals.org/content/13/3>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.